Table I.
Patients’ characteristics
| Characteristics | D + P (N = 118) | C + P (N = 118) | ||
|---|---|---|---|---|
| n | % | n | % | |
| Age: | ||||
| Median | 56 | 57 | ||
| Range | 32–71 | 34–71 | ||
| Years: | ||||
| 18–39 | 4 | 3.39 | 3 | 2.54 |
| 40–55 | 49 | 41.53 | 51 | 43.22 |
| 56–70 | 65 | 55.08 | 64 | 54.24 |
| Gender: | ||||
| Male | 82 | 69.49 | 93 | 78.81 |
| Female | 36 | 30.51 | 25 | 21.19 |
| ECOG PS: | ||||
| 0 | 14 | 11.86 | 11 | 9.32 |
| 1 | 95 | 80.51 | 91 | 77.12 |
| 2 | 9 | 7.63 | 16 | 13.56 |
| Lung stage: | ||||
| Stage IIIB | 37 | 31.36 | 46 | 38.98 |
| Stage IV | 81 | 68.64 | 72 | 61.02 |
| Pathological type: | ||||
| Squamous | 39 | 33.05 | 43 | 36.44 |
| Nonsquamous | 79 | 66.95 | 75 | 63.56 |
| Previous medical history: | ||||
| Yes | 114 | 96.61 | 116 | 98.31 |
| No | 4 | 3.39 | 2 | 1.69 |
| NSCLC symptoms: | ||||
| Present | 112 | 94.92 | 115 | 97.46 |
| Absent | 6 | 5.08 | 3 | 2.54 |
| Number of tumors: | ||||
| 1 | 74 | 62.71 | 78 | 66.10 |
| 2 | 34 | 28.81 | 30 | 25.42 |
| 3 or more | 10 | 8.48 | 10 | 8.48 |
No significant differences between D + P and C + P characteristics. D + P – dicycloplatin plus paclitaxel, C + P – carboplatin plus paclitaxel